Moriyama T, Wada M, Urade R, Kito M, Katunuma N, Ogawa T, Simoni R D
Research Institute for Food Science, Kyoto University, Gokasho, Japan.
Arch Biochem Biophys. 2001 Feb 15;386(2):205-12. doi: 10.1006/abbi.2000.2209.
We have recently shown that 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, an endoplasmic reticulum (ER) membrane protein, is degraded in ER membranes prepared from sterol pretreated cells and that such degradation is catalyzed by a cysteine protease within the reductase membrane domain. The use of various protease inhibitors suggested that degradation of HMG-CoA reductase in vitro is catalyzed by a cathepsin L-type cysteine protease. Purified ER contains E-64-sensitive cathepsin L activity whose inhibitor sensitivity was well matched to that of HMG-CoA reductase degradation in vitro. CLIK-148 (cathepsin L inhibitor) inhibited degradation of HMG-CoA reductase in vitro. Purified cathepsin L also efficiently cleaved HMG-CoA reductase in isolated ER preparations. To determine whether a cathepsin L-type cysteine protease is involved in sterol-regulated degradation of HMG-CoA reductase in vivo, we examined the effect of E-64d, a membrane-permeable cysteine protease inhibitor, in living cells. While lactacystin, a proteasome-specific inhibitor, inhibited sterol-dependent degradation of HMG-CoA reductase, E-64d failed to do so. In contrast, degradation of HMG-CoA reductase in sonicated cells was inhibited by E-64d, CLIK-148, and leupeptin but not by lactacystin. Our results indicate that HMG-CoA reductase is degraded by the proteasome under normal conditions in living cells and that it is cleaved by cathepsin L leaked from lysosomes during preparation of the ER, thus clarifying the apparently paradoxical in vivo and in vitro results. Cathepsin L-dependent proteolysis was observed to occur preferentially in sterol-pretreated cells, suggesting that sterol treatment results in conformational changes in HMG-CoA reductase that make it more susceptible to such cleavage.
我们最近发现,3-羟基-3-甲基戊二酰辅酶A(HMG-CoA)还原酶是一种内质网(ER)膜蛋白,在由经固醇预处理的细胞制备的ER膜中会被降解,且这种降解是由还原酶膜结构域内的一种半胱氨酸蛋白酶催化的。使用各种蛋白酶抑制剂表明,体外HMG-CoA还原酶的降解是由组织蛋白酶L型半胱氨酸蛋白酶催化的。纯化的内质网含有对E-64敏感的组织蛋白酶L活性,其抑制剂敏感性与体外HMG-CoA还原酶降解的抑制剂敏感性非常匹配。CLIK-148(组织蛋白酶L抑制剂)在体外抑制了HMG-CoA还原酶的降解。纯化的组织蛋白酶L在分离的内质网制剂中也能有效切割HMG-CoA还原酶。为了确定组织蛋白酶L型半胱氨酸蛋白酶是否参与体内HMG-CoA还原酶的固醇调节降解,我们研究了膜通透性半胱氨酸蛋白酶抑制剂E-64d对活细胞的影响。虽然蛋白酶体特异性抑制剂乳胞素抑制了HMG-CoA还原酶的固醇依赖性降解,但E-64d未能做到这一点。相反,E-64d、CLIK-148和亮抑蛋白酶肽抑制了超声处理细胞中HMG-CoA还原酶的降解,但乳胞素没有。我们的结果表明,在正常条件下,活细胞中的HMG-CoA还原酶被蛋白酶体降解,并且在制备内质网期间,它会被从溶酶体中泄漏的组织蛋白酶L切割,从而澄清了体内和体外结果中明显矛盾的现象。观察到组织蛋白酶L依赖性蛋白水解优先发生在经固醇预处理的细胞中,这表明固醇处理导致HMG-CoA还原酶构象改变,使其更容易受到这种切割。